Clinical Trial Update: Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MEDI-522 with or without dacarbazine for metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dacarbazine (dacarbazine)
• MEDI-522

Snippet

Sponsor: MedImmune LLC | Conditions: Melanoma, Malignant Metastatic Melanoma | Phase 2 | Status: COMPLETED